Revel Pharmaceuticals develops therapeutics for multiple diseases of aging including osteoarthritis, kidney, and complications of diabetes.
Revel Pharmaceuticals has raised $84K in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2025.
Revel Pharmaceuticals's investors include Gaingels, Starbloom Capital, KIZOO Technology Capital, Tubus.
Revel Pharmaceuticals is headquartered in San Francisco, United States.
Revel Pharmaceuticals develops therapeutics for multiple diseases of aging including osteoarthritis, kidney, and complications of diabetes.
Revel Pharmaceuticals is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Revel Pharmaceuticals — Funding & Investors." VCBacked, October 7, 2025, https://www.vcbacked.co/company/revel-pharmaceuticals. Accessed September 30, 2026.
VCBacked. (2025). Revel Pharmaceuticals — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/revel-pharmaceuticals
{{cite web |title=Revel Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/revel-pharmaceuticals |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated